

Summary of Consolidated Financial Results for the Nine Months Ended December 31, 2025 [IFRS]

February 4, 2026

Company name:	TEIJIN LIMITED (Stock code 3401)	https://www.teijin.com
Stock exchange listing:	Tokyo (Prime Market)	
Representative:	Akimoto Uchikawa President and CEO	
Contact person:	Tetsuji Mikami Deputy General Manager, Corporate Communication Department (Responsible for Investor Relations)	
Telephone number:	+81-(0)3-3506-4395	
Scheduled date for dividends payment:	—	
Availability of supplementary information for the quarterly financial results:	Yes	
Organization of briefing on the quarterly financial results:	Yes (for analysts and institutional investors)	

(Amounts rounded to the nearest million yen)

1. Highlight of the Third Quarter of FY2025 (April 1, 2025 through December 31, 2025)

(1) Consolidated financial results

(Percentages are year-on-year changes)

	Revenue		Adjusted operating income		Operating income		Profit before tax	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
For the nine months ended December 31, 2025	659,878	(12.7)	23,830	(7.0)	(53,773)	—	(55,879)	—
For the nine months ended December 31, 2024	756,112	6.7	25,632	46.7	(43,727)	—	(45,367)	—

	Profit for the period		Profit attributable to owners of parent		Comprehensive income	
	Million yen	%	Million yen	%	Million yen	%
For the nine months ended December 31, 2025	(58,911)	—	(58,970)	—	(34,624)	—
For the nine months ended December 31, 2024	52,628	320.2	50,980	376.6	57,260	66.1

Note: Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
For the nine months ended December 31, 2025	(305.81)	(305.81)
For the nine months ended December 31, 2024	264.66	264.66

(2) Consolidated financial position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent
	Million yen	Million yen	Million yen	%
As of December 31, 2025	989,641	391,194	387,051	39.1
As of March 31, 2025	1,061,272	438,541	431,378	40.6

2. Dividends

	Dividends per share				
Period	1Q	2Q	3Q	4Q	Annual
	Yen	Yen	Yen	Yen	Yen
FY2024	—	25.00	—	25.00	50.00
FY2025	—	25.00	—		
FY2025 (outlook)				25.00	50.00

Note: Revision of outlook for dividends in the third quarter: None

3. Forecast for Operating Results in the Fiscal Year Ending March 31, 2026 (FY 2025)

(Percentages are year-on-year changes)

	Revenue		Adjusted operating income		Operating income		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
FY2025 annual	860,000	(14.5)	25,000	(9.4)	5,000	—	(10,000)	—	(51.85)

Note: Revision of outlook for FY2025 consolidated operating results in the third quarter: None

■ Notes

(1) Significant changes in the scope of consolidation for the nine months ended December 31, 2025: Yes

Newly included: None

Excluded: 2 companies (Teijin Nakashima Medical Co., Ltd., Teijin Automotive Technologies NA Holdings Corp.)

(2) Changes in accounting policies or changes in accounting estimates

a. Changes in accounting policies required by IFRS None

b. Changes in accounting policies other than the above a: None

c. Changes in accounting estimates: None

(3) Shares issued (common shares)

a. Number of shares issued and outstanding (including treasury shares)

As of December 31, 2025: 197,953,707 shares

As of March 31, 2025: 197,953,707 shares

b. Number of treasury shares

As of December 31, 2025: 5,050,129 shares

As of March 31, 2025: 5,236,834 shares

c. Average number of issued and outstanding shares during the period

The nine months ended December 31, 2025: 192,831,528 shares

The nine months ended December 31, 2024: 192,625,507 shares

■ Review by certified public accountants or an audit firm for the attached quarterly consolidated financial statements:

None

■ Appropriate use of forecast and other information and other matters

(Caution regarding all forecasts in this document)

All forecasts in this document are based on management's assumptions in light of information currently available and involve certain risks and uncertainties. Moreover, the Company does not guarantee the achievement of these forecasts and actual results could differ materially from these forecasts.

(Quarterly supplementary financial information and contents of quarterly business results presentation)

(1) Quarterly supplementary financial information is disclosed on TDnet (Timely Disclosure network) and on our company's website on the same day.

(2) Quarterly business results presentation will be disclosed on our company's website.

Supplementary Information

Table of Contents

1. The Overview of Results of Operations, etc.	2
2. Condensed Quarterly Consolidated Financial Statements and Notes Thereto	3
(1) Condensed Quarterly Consolidated Statements of Financial Position	3
(2) Condensed Quarterly Consolidated Statements of Profit or Loss and Condensed Quarterly Consolidated Statements of Comprehensive Income	5
(3) Condensed Quarterly Consolidated Statements of Changes in Equity	7
(4) Condensed Quarterly Consolidated Statements of Cash Flows	11
(5) Notes to the Condensed Quarterly Consolidated Financial Statements	13
(Note on Going Concern Assumptions)	13
(Segment Information)	13
(Assets Held for Sale and Discontinued Operations)	15
(Impairment of Non-Financial Assets)	17
(Loss of Control)	18
(Earnings Per Share)	20
(Significant Subsequent Events)	20

1. The Overview of Results of Operations, etc.

The overview of consolidated results of operations, etc., for the third quarter of the fiscal year ending March 31, 2026, is disclosed on our company's website and on TDnet (Timely Disclosure network) today through Flash Report Results of FY2025 3Q & Outlook for FY2025.

2. Condensed Quarterly Consolidated Financial Statements and Notes Thereto

(1) Condensed Quarterly Consolidated Statements of Financial Position

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Assets		
Current assets		
Cash and cash equivalents	107,538	122,166
Trade and other receivables	166,741	169,831
Inventories	227,032	224,060
Other financial assets	8,499	12,146
Other current assets	22,685	30,872
Subtotal	532,496	559,076
Assets held for sale	55,388	14,120
Total current assets	587,883	573,196
Non-current assets		
Property, plant and equipment	250,945	220,621
Right-of-use assets	23,333	20,120
Goodwill	8,334	8,564
Intangible assets	85,511	75,464
Investment property	11,888	10,402
Investments accounted for using the equity method	45,602	37,430
Other financial assets	26,481	29,462
Retirement benefit asset	728	734
Deferred tax assets	16,977	10,035
Other non-current assets	3,589	3,612
Total non-current assets	473,389	416,445
Total assets	1,061,272	989,641

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	105,296	99,378
Bonds and borrowings	124,985	170,881
Lease liabilities	7,954	7,647
Other financial liabilities	5,473	13,008
Income taxes payable	3,693	2,869
Provisions	1,798	1,859
Other current liabilities	38,147	35,418
Subtotal	287,347	331,059
Liabilities directly associated with assets held for sale	31,616	3,004
Total current liabilities	318,962	334,063
Non-current liabilities		
Bonds and borrowings	237,494	191,667
Lease liabilities	16,694	18,143
Other financial liabilities	4,729	5,366
Retirement benefit liability	32,375	37,132
Provisions	992	1,337
Deferred tax liabilities	3,268	3,812
Other non-current liabilities	8,215	6,926
Total non-current liabilities	303,768	264,383
Total liabilities	622,731	598,447
Equity		
Share capital	71,833	71,833
Capital surplus	105,708	105,667
Retained earnings	231,726	164,150
Treasury shares	(11,411)	(11,002)
Other components of equity	34,655	55,517
Other comprehensive income associated with assets held for sale	(1,134)	887
Total equity attributable to owners of parent	431,378	387,051
Non-controlling interests	7,164	4,144
Total equity	438,541	391,194
Total liabilities and equity	1,061,272	989,641

(2) Condensed Quarterly Consolidated Statements of Profit or Loss and Condensed Consolidated Statements of Comprehensive Income
(Condensed Consolidated Statements of Profit or Loss)

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Continuing operations		
Revenue	756,112	659,878
Cost of sales	(618,768)	(543,459)
Gross profit	137,343	116,419
Selling, general and administrative expenses	(180,689)	(158,670)
Other income	1,530	5,086
Other expenses	(1,911)	(16,607)
Operating income (loss)	(43,727)	(53,773)
Finance income	4,278	3,176
Finance costs	(8,794)	(7,697)
Share of profit of investments accounted for using the equity method	2,876	2,414
Profit(loss) before tax	(45,367)	(55,879)
Income tax expense	(8,063)	(3,031)
Profit(loss) from continuing operations	(53,430)	(58,911)
Discontinued operations		
Profit from discontinued operations	106,058	—
Profit(loss)	52,628	(58,911)
Profit(loss) attributable to:		
Owners of parent	50,980	(58,970)
Non-controlling interests	1,648	60
Profit(loss)	52,628	(58,911)
Earnings(loss) per share		
Basic earnings(loss) per share		
Continuing operations	(276.94)	(305.81)
Discontinued operations	541.60	—
Total	264.66	(305.81)
Diluted earnings(loss) per share		
Continuing operations	(276.94)	(305.81)
Discontinued operations	541.60	—
Total	264.66	(305.81)

(Condensed Quarterly Consolidated Statements of Comprehensive Income)

For the nine months ended December 31, 2024 and 2025

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Profit(loss)	52,628	(58,911)
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	1,043	2,454
Remeasurements of defined benefit plans	(0)	191
Share of other comprehensive income of investments accounted for using the equity method	(61)	7
Total of items that will not be reclassified to profit or loss	982	2,652
Items that may be reclassified to profit or loss		
Effective portion of cash flow hedges	446	(1,667)
Exchange differences on translation of foreign operations	1,276	23,231
Share of other comprehensive income of investments accounted for using the equity method	1,927	72
Total of items that may be reclassified to profit or loss	3,650	21,635
Total other comprehensive income, net of tax	4,632	24,287
Comprehensive income	57,260	(34,624)
Comprehensive income attributable to:		
Owners of parent	55,624	(34,688)
Non-controlling interests	1,636	64
Comprehensive income	57,260	(34,624)

(3) Condensed Quarterly Consolidated Statements of Changes in Equity

For the nine months ended December 31, 2024

(Millions of yen)

	Equity attributable to owners of parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Share acquisition rights	Financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance as of April 1, 2024	71,833	103,133	204,174	(11,772)	474	14,541	—
Profit(loss)	—	—	50,980	—	—	—	—
Other comprehensive income	—	—	—	—	—	998	(0)
Total comprehensive income	—	—	50,980	—	—	998	(0)
Purchase of treasury shares	—	—	—	(5)	—	—	—
Disposal of treasury shares	—	(24)	—	91	(264)	—	—
Transfer of loss on disposal of treasury shares	—	101	(101)	—	—	—	—
Share-based payment expenses	—	123	—	213	—	—	—
Dividends	—	—	(7,705)	—	—	—	—
Change in treasury shares of parent arising from transactions with non-controlling interests	—	2,347	—	—	—	—	—
Transfer to non-financial assets	—	—	—	—	—	—	—
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—	—	—	—
Change in scope of consolidation	—	—	(408)	—	—	408	—
Transfer from other components of equity to retained earnings	—	—	6,711	—	—	(6,711)	0
Other	—	(0)	0	0	—	—	—
Total transactions with owners	—	2,548	(1,503)	299	(264)	(6,303)	0
Balance as of December 31, 2024	71,833	105,681	253,651	(11,473)	210	9,236	—

(Millions of yen)

	Equity attributable to owners of parent						
	Other components of equity			Other comprehensive income associated with assets held for sale	Total equity attributable to owners of parent	Non-controlling interests	Total equity
	Effective portion of cash flow hedges	Exchange differences on translation of foreign operations	Other				
Balance as of April 1, 2024	332	26,792	42,139	—	409,507	27,252	436,759
Profit(loss)	—	—	—	—	50,980	1,648	52,628
Other comprehensive income	446	3,200	4,644	—	4,644	(12)	4,632
Total comprehensive income	446	3,200	4,644	—	55,624	1,636	57,260
Purchase of treasury shares	—	—	—	—	(5)	—	(5)
Disposal of treasury shares	—	—	(264)	—	(197)	—	(197)
Transfer of loss on disposal of treasury shares	—	—	—	—	—	—	—
Share-based payment expenses	—	—	—	—	336	—	336
Dividends	—	—	—	—	(7,705)	(515)	(8,220)
Change in treasury shares of parent arising from transactions with non-controlling interests	—	—	—	—	2,347	(2,341)	6
Transfer to non-financial assets	(39)	—	(39)	—	(39)	—	(39)
Transfer to other comprehensive income associated with assets held for sale	—	8,184	8,184	(8,184)	—	—	—
Change in scope of consolidation	—	—	408	—	—	(19,190)	(19,190)
Transfer from other components of equity to retained earnings	—	—	(6,711)	—	—	—	—
Other	—	—	(0)	—	0	16	17
Total transactions with owners	(39)	8,184	1,577	(8,184)	(5,263)	(22,030)	(27,293)
Balance as of December 31, 2024	739	38,176	48,360	(8,184)	459,867	6,858	466,725

For the nine months ended December 31, 2025

(Millions of yen)

	Equity attributable to owners of parent						
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity		
					Share acquisition rights	Financial assets measured at fair value through other comprehensive income	Remeasurements of defined benefit plans
Balance as of April 1, 2025	71,833	105,708	231,726	(11,411)	162	8,891	—
Profit(loss)	—	—	(58,970)	—	—	—	—
Other comprehensive income	—	—	—	—	—	2,461	191
Total comprehensive income	—	—	(58,970)	—	—	2,461	191
Purchase of treasury shares	—	—	—	(3)	—	—	—
Disposal of treasury shares	—	(13)	—	47	(34)	—	—
Transfer of loss on disposal of treasury shares	—	184	(184)	—	—	—	—
Share-based payment expenses	—	(212)	—	365	—	—	—
Dividends	—	—	(9,640)	—	—	—	—
Change in treasury shares of parent arising from transactions with non-controlling interests	—	—	—	—	—	—	—
Transfer to non-financial assets	—	—	—	—	—	—	—
Transfer to other comprehensive income associated with assets held for sale	—	—	—	—	—	(162)	—
Change in scope of consolidation	—	—	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	1,218	—	—	(1,028)	(191)
Other	—	—	0	—	—	—	—
Total transactions with owners	—	(41)	(8,606)	409	(34)	(1,189)	(191)
Balance as of December 31, 2025	71,833	105,667	164,150	(11,002)	128	10,163	—

(Millions of yen)

	Equity attributable to owners of parent						
	Other components of equity			Other comprehensive income associated with assets held for sale	Total equity attributable to owners of parent	Non-controlling interests	Total equity
	Effective portion of cash flow hedges	Exchange differences on translation of foreign operations	Other				
Balance as of April 1, 2025	930	24,672	34,655	(1,134)	431,378	7,164	438,541
Profit(loss)	—	—	—	—	(58,970)	60	(58,911)
Other comprehensive income	(1,667)	23,298	24,283	—	24,283	4	24,287
Total comprehensive income	(1,667)	23,298	24,283	—	(34,688)	64	(34,624)
Purchase of treasury shares	—	—	—	—	(3)	—	(3)
Disposal of treasury shares	—	—	(34)	—	0	—	0
Transfer of loss on disposal of treasury shares	—	—	—	—	—	—	—
Share-based payment expenses	—	—	—	—	153	—	153
Dividends	—	—	—	—	(9,640)	(40)	(9,680)
Change in treasury shares of parent arising from transactions with non-controlling interests	—	—	—	—	—	—	—
Transfer to non-financial assets	(149)	—	(149)	—	(149)	—	(149)
Transfer to other comprehensive income associated with assets held for sale	—	(725)	(887)	887	—	—	—
Change in scope of consolidation	—	(1,134)	(1,134)	1,134	—	(3,044)	(3,044)
Transfer from other components of equity to retained earnings	—	—	(1,218)	—	—	—	—
Other	—	—	—	—	0	—	0
Total transactions with owners	(149)	(1,859)	(3,421)	2,020	(9,639)	(3,084)	(12,723)
Balance as of December 31, 2025	(885)	46,111	55,517	887	387,051	4,144	391,194

(4) Condensed Quarterly Consolidated Statements of Cash Flows

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Cash flows from operating activities		
Profit (loss) before tax	(45,367)	(55,879)
Profit before tax from discontinued operations	106,601	—
Depreciation and amortization	54,393	46,148
Impairment losses	59,126	60,839
Share of loss (profit) of investments accounted for using the equity method	(2,834)	(2,414)
Increase or decrease in retirement benefit asset or liability	(124)	3,752
Interest and dividend income	(2,709)	(3,018)
Interest expenses	8,119	5,383
Loss (gain) on sale or disposal of fixed assets	1,163	(1,190)
Loss (gain) on sale of shares of subsidiaries	(102,060)	10,624
Decrease (increase) in trade and other receivables	17,726	3,975
Decrease (increase) in inventories	(18,586)	14,007
Increase (decrease) in trade and other payables	(15,240)	(9,967)
Other	1,048	2,538
Subtotal	61,255	74,799
Interest and dividends received	7,352	8,571
Proceeds from insurance income	520	—
Interest paid	(7,456)	(5,159)
Income taxes paid	(20,842)	(5,037)
Net cash provided by (used in) operating activities	40,829	73,173
Cash flows from investing activities		
Purchase of property, plant and equipment	(41,809)	(43,939)
Proceeds from sale of property, plant and equipment	624	3,222
Purchase of intangible assets	(2,482)	(4,667)
Purchase of investment securities	(3,519)	(854)
Proceeds from sale of investment securities	11,997	1,748
Net decrease (increase) in short-term loans receivable	(707)	(1,012)
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	96,071	4,052
Other	(992)	(614)
Cash flows from investing activities	59,183	(42,063)

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term borrowings	53,974	29,289
Proceeds from long-term borrowings	1,000	—
Repayments of long-term borrowings	(34,516)	(36,793)
Redemption of bonds	(20,090)	—
Repayments of lease liabilities	(5,276)	(4,418)
Purchase of treasury shares	(5)	(3)
Dividends paid to owners of parent	(7,705)	(9,640)
Dividends paid to non-controlling interests	(678)	(40)
Net cash provided by (used in) financing activities	(13,296)	(21,605)
Effect of exchange rate changes on cash and cash equivalents	1,511	3,411
Net increase (decrease) in cash and cash equivalents	88,227	12,915
Cash and cash equivalents at beginning of period	123,212	107,538
Net increase (decrease) in cash and cash equivalents included in assets held for sale	(1,808)	1,712
Cash and cash equivalents at end of period	209,631	122,166

(5) Notes to the Condensed Quarterly Consolidated Financial Statements

(Note on Going Concern Assumptions)

Not applicable.

(Segment Information)

(1) Overview of reportable segments

The Teijin Group's reportable operating segments are the components of the Teijin Group for which separate financial information is available and evaluated regularly by its Board of Directors in determining the allocation of management resources and in assessing performance.

The Teijin Group currently divides its operations into business fields, based on type of product, nature of business, and services provided. For the products and services of each business field, the Teijin Group formulates comprehensive strategies, in Japan and overseas, to drive its business activities forward.

Accordingly, the Teijin Group divides its operations into reportable operating segments on the same basis as it uses internally so the Teijin Group sets the three reportable segments, which are "Materials," "Fibers & Products Converting," and "Healthcare."

"Materials" involves the production and sale of aramid fibers, polycarbonate resin, carbon fibers, and composites, while "Fibers & Products Converting" involves the production and sale of polyester fibers and fiber products, etc. "Healthcare" includes the production and sale of pharmaceuticals and medical devices, etc. and the provision of home healthcare services.

(2) Segment revenue and performance

Results of the Third Quarter of FY2024 (April 1, 2024, through December 31, 2024)

(Millions of yen)

	Reportable operating segments				Others (Note 1)	Total	Adjustments (Note 2)	Amount on condensed quarterly consolidated financial statements
	Materials	Fibers & Products Converting	Healthcare	Subtotal				
Revenue								
External	342,359	266,178	104,231	712,768	43,345	756,112	—	756,112
Intersegment	8,324	1,734	4	10,061	3,687	13,749	(13,749)	—
Total	350,682	267,912	104,234	722,828	47,032	769,860	(13,749)	756,112
Adjusted operating income (Note 3)	1,865	15,143	8,049	25,057	6,707	31,764	(6,132)	25,632

Note 1. "Others," which includes battery materials & membrane field and regenerative medicine & implantable medical device field, does not qualify as a reportable operating segment.

Note 2. Adjustments of the adjusted operating income of (6,132) million yen include the elimination of intersegment transactions of (77) million yen and corporate expenses of (6,055) million yen. Corporate expenses are mainly expenses related to administrative divisions of the head office that are not attributable to the reportable segments.

Note 3. Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to non-recurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

Results of the Third Quarter of FY2025 (April 1, 2025 through December 31, 2025)

(Millions of yen)

	Reportable operating segments				Others (Note 1)	Total	Adjustments (Note 2)	Amount on condensed quarterly consolidated financial statements
	Materials	Fibers & Products Converting	Healthcare	Subtotal				
Revenue								
External	259,414	258,599	105,799	623,812	36,066	659,878	—	659,878
Intersegment	8,211	1,763	—	9,974	2,777	12,752	(12,752)	—
Total	267,626	260,362	105,799	633,786	38,843	672,629	(12,752)	659,878
Adjusted operating income (Note 3)	481	13,243	12,933	26,657	4,190	30,847	(7,016)	23,830

Note 1. "Others," which includes battery materials & membrane field and regenerative medicine & implantable medical device field, does not qualify as a reportable operating segment.

Note 2. Adjustments of the adjusted operating income of (7,016) million yen include the elimination of intersegment transactions of (27) million yen and corporate expenses of (6,989) million yen. Corporate expenses are mainly expenses related to administrative divisions of the head office that are not attributable to the reportable segments.

Note 3. Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to non-recurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

The adjustment from adjusted operating income to profit before tax is as follows:

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Adjusted operating income	25,632	23,830
Gain on sale of fixed assets	405	1,920
Loss on disposal of fixed assets	(1,567)	(730)
Impairment losses	(59,126)	(60,839)
Special retirement benefits (Note 1)	(4,593)	(3,357)
Loss (gain) on sale of shares of affiliates	—	(10,624)
Share of loss(profit) of investments accounted for using the equity method (Note 2)	(4,230)	(2,706)
Other	(248)	(1,266)
Operating income (loss)	(43,727)	(53,773)
Finance income	4,278	3,176
Finance costs	(8,794)	(7,697)
Share of profit (loss) of investments accounted for using the equity method	2,876	2,414
Profit (loss) before tax	(45,367)	(55,879)

Note 1. "Special retirement benefits" for FY2024, mainly relate to Early Retirement Incentive Program.

"Special retirement benefits" for FY2025, mainly relate to business structural reform.

Note 2. Adjusted operating income is calculated by adding share of profit (loss) of investments accounted for using the equity method to operating income and excluding gains and losses due to nonrecurring factors, which include nonrecurring gains and losses such as financial gains and losses and impairment losses in share of profit (loss) of investments accounted for using the equity method.

(Assets Held for Sale and Discontinued Operations)

(1) Assets held for sale and liabilities directly associated with assets held for sale

A. Assets held for sale and liabilities directly associated with assets held for sale are comprised of the following:

(Millions of yen)

	As of March 31, 2025	As of December 31, 2025
Assets held for sale		
Cash and cash equivalents	1,798	86
Trade and other receivables	24,518	1,149
Inventories	16,015	104
Other current assets	3,977	22
Property, plant and equipment	3,105	1,773
Right-of-use assets	349	948
Goodwill	86	—
Intangible assets	605	73
Investments accounted for using the equity method	2,959	8,457
Other financial assets (non-current)	20	411
Retirement benefit asset	755	—
Deferred tax assets	1,089	457
Other non-current assets	113	16
Investment property	—	624
Total	55,388	14,120
Liabilities directly associated with assets held for sale		
Trade and other payables	21,461	1,240
Bonds and borrowings (current)	1,000	—
Lease liabilities (current)	666	281
Other financial liabilities (current)	374	50
Income taxes payable	329	—
Provisions (current)	179	—
Other current liabilities	2,467	160
Bonds and borrowings (non-current)	309	—
Lease liabilities (non-current)	3,551	636
Retirement benefit liability	816	239
Provisions (non-current)	245	—
Deferred tax liabilities	98	387
Other non-current liabilities	120	12
Total	31,616	3,004

B. Overview of assets held for sale

The assets held for sale as of December 31, 2025 mainly consist of investments that were previously accounted for using the equity method. The main components of these assets are investments in DuPont Teijin Advanced Papers (Japan) Limited (hereinafter, "DTPJ") and DuPont Teijin Advanced Papers (Asia) Limited (hereinafter, "DTPA") within the Other segment. DTPJ and DTPA have been engaged in the aramid paper business with DuPont de Nemours, Inc. (hereinafter, "DuPont"), manufacturing, processing, and selling synthetic paper and pressboard made from meta-aramid material. Following DuPont's indication of its intention to exit its aramid operations—including the aramid paper joint ventures—The Company has decided to divest its equity interests in DTPJ and DTPA to DuPont in August 2025. Accordingly, the application of the equity method to these interests has been discontinued, and the interests scheduled for divestment have been reclassified as assets held for sale.

(2) Discontinued operations

A. Overview of discontinued operations

At the Board of Directors' meeting held on June 18, 2024, the Company resolved to conclude a basic agreement on transferring all INFOCOM Shares (hereinafter, "INFOCOM Shares") that it owns to INFOCOM CORPORATION (hereinafter, "INFOCOM").

As a result, the Company has classified the profit and loss, and cash flows of the "IT" Business including INFOCOM and its consolidated subsidiaries to discontinued operations for the nine months ended December 31, 2024.

The transfer of the INFOCOM Shares was completed on October 22, 2024.

B. Profit or loss related to discontinued operations

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Discontinued operations		
Revenue (Note)	146,354	—
Expenses	(39,753)	—
Profit before tax from discontinued operations	106,601	—
Income tax expense (Note)	(543)	—
Profit (loss) from discontinued operations	106,058	—

Note: A gain on the sale of the IT business amounting to 102,060 million yen is included during the nine months ended December 31, 2024. The income tax related to the gain is 684 million yen on the profit side.

C. Cash flows from discontinued operations

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Cash flows from discontinued operations		
Cash flows from operating activities	4,015	—
Cash flows from investing activities (Note)	93,685	—
Cash flows from financing activities	(1,813)	—
Net cash flow from discontinued operations	95,887	—

Note: A cash inflow of 96,071 million yen resulting from the sale of the IT business is included during the nine months ended December 31, 2024.

(Impairment of Non-Financial Assets)

The Company recognized the impairment loss of 60,839 million yen for the nine months ended December 31, 2025. The major items are as follows:

(1) Fixed assets of the Twaron Business

An impairment loss of 49,509 million yen was recognized for the fixed assets of Twaron Business under the Materials segment. The impairment loss of 39,942 million yen and 9,567 million yen were included in "Cost of sales" and "Selling, general and administrative expenses," respectively. With regard to the Twaron Business, factors such as intensified competition in main applications and the appreciation of the euro, driven by uncertainties in US trade policy, have also had an impact. Consequently, it is now expected that achieving the short-term plan will be difficult. Therefore, indications of impairment were identified, and as a result of an impairment test, the recoverable amount of the fixed assets of the business was determined to be lower than their carrying amounts. Therefore, the impairment loss on the fixed assets was recognized.

(2) Fixed assets of the Carbon Fibers Business

An impairment loss of 7,323 million yen was recognized for the fixed assets of Carbon Fibers Business under the Materials segment. The impairment loss of 6,942 million yen and 381 million yen were included in "Cost of sales" and "Selling, general and administrative expenses," respectively. As for the Carbon Fibers Business, the supply-demand balance, mainly for general-purpose applications, has continued to soften due to intensified competition, and market prices have continued to decline. As a result, it has become necessary to transform the business structure into one that is less susceptible to changes in the business environment. In this context, as part of a fundamental cost structure reform aimed at stabilizing earnings, the Company decided to review its global production system and temporarily suspend operations at its carbon fiber manufacturing site in the United States. Under these circumstances, indications of impairment were identified in the Carbon Fibers Business, and as a result of an impairment test, the recoverable amount of the fixed assets of the business was determined to be lower than their carrying amounts. Therefore, the impairment loss on the fixed assets was recognized.

(Loss of Control)

Results of the Third Quarter of FY2024 (April 1, 2024, through December 31, 2024)

(1) Overview of the loss of control

Based on the basic agreement on transactions concluded with BXJC II Holding KK on June 18, 2024, regarding (i) the Company shall not apply to a tender offer that the Tender Offeror plans to make for the common shares of INFOCOM CORPORATION (hereinafter, "INFOCOM"), which is the Company's consolidated subsidiary, (hereinafter, "INFOCOM Shares") and stock acquisition rights (hereinafter, "Tender Offer") with regard to all INFOCOM Shares that the Company owns, (ii) procedures shall be implemented to make the Company and the Tender Offeror INFOCOM's only shareholders after the completion of the Tender Offer, and (iii) the Company shall transfer all INFOCOM Shares that it owns at the time to INFOCOM through share repurchase by INFOCOM (hereinafter, "Share Transfer"), on October 22, 2024, the Company transferred all of its shares in INFOCOM to INFOCOM through INFOCOM's repurchase of its own shares.

As a result of the share transfer, the Company's ownership interest has become zero, and the Company has lost control over INFOCOM and its subsidiaries (hereinafter, "INFOCOM group").

(2) Assets and liabilities with the loss of control over the INFOCOM group

(Millions of yen)

Account Item	Amount
Breakdown of assets at the time of losing control	
Current assets	57,202
Non-current assets	22,342
Breakdown of liabilities at the time of losing control	
Current liabilities	26,688
Non-current liabilities	2,772

(3) Income (loss) arising from the loss of control over the INFOCOM Group

(Millions of yen)

Account Item	Amount
Gain recognized with the loss of control	103,824
Transaction costs associated with the sale	(1,764)
Gain on the sale of subsidiary shares	102,060

(4) Changes in cash and cash equivalents with the loss of control

(Millions of yen)

Account Item	Amount
Cash consideration received	132,613
Cash and cash equivalents in subsidiaries excluded from the scope of consolidation	(36,542)
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	96,071

Results of the Third Quarter of FY2025 (April 1, 2025, through December 31, 2025)

(Share transfer of Teijin Nakashima Medical Co., Ltd.)

(1) Overview of the loss of control

On June 16, 2025, based on the share transfer agreement concluded with Nakashima Holdings. Co., Ltd. (hereinafter, "Nakashima") and Teijin Nakashima Medical Co., Ltd. (hereinafter, "Teijin Nakashima Medical") on April 25, 2025, the Company transferred all of its shares in Teijin Nakashima Medical to Nakashima and Teijin Nakashima Medical, respectively. As a result of the share transfer, the Company's ownership interest has become zero, and the Company has lost control over Teijin Nakashima Medical.

(2) Assets and liabilities with the loss of control

(Millions of yen)

Account Item	Amount
Breakdown of assets at the time of losing control	
Current assets	6,759
Non-current assets	4,152
Breakdown of liabilities at the time of losing control	
Current liabilities	4,224
Non-current liabilities	578

(3) Income (loss) arising from the loss of control

(Millions of yen)

Account Item	Amount
Gain recognized with the loss of control	795
Transaction costs associated with the sale	(97)
Gain on sale of shares of affiliates	698

(4) Changes in cash and cash equivalents with the loss of control

(Millions of yen)

Account Item	Amount
Cash consideration received	3,753
Cash and cash equivalents in subsidiaries excluded from the scope of consolidation	(1,100)
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	2,652

(Share transfer of Teijin Automotive Technologies NA Holdings Corp.)

(1) Overview of the loss of control

On July 1, 2025, based on the share transfer agreement concluded with Stork BidCo Inc. on March 31, 2025, a special purpose company under AURELIUS Private Equity Mid-Market Buyout, Teijin Holdings USA Inc., the Company's wholly owned subsidiary, transferred all of its shares in Teijin Automotive Technologies NA Holdings Corporation (hereinafter, "TAT") to Stork BidCo Inc. As a result of the share transfer, the Company's ownership interest has become zero, and the Company has lost control over TAT.

(2) Assets and liabilities with the loss of control

(Millions of yen)

Account Item	Amount
Breakdown of assets at the time of loss of control	
Current assets	39,651
Non-current assets	1,575
Breakdown of liabilities at the time of loss of control	
Current liabilities	33,360
Non-current liabilities	25,581

(3) Income (loss) arising from the loss of control

(Millions of yen)

Account Item	Amount
Loss recognized with the loss of control	(9,615)
Transaction costs associated with the sale	(1,489)
Loss on sale of shares of affiliates	(11,104)

(4) Changes in cash and cash equivalents with the loss of control

(Millions of yen)

Account Item	Amount
Cash consideration received	745
Cash and cash equivalents in subsidiaries excluded from the scope of consolidation	(15)
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	730

The final transfer price was determined in late January, reflecting the results of the working capital adjustment. Consequently, (3) Income (loss) arising from the loss of control was largely finalized in the third quarter of the fiscal year ending March 31, 2026. On the other hand, due to the actual cash payments to be made in the fourth quarter of the fiscal year ending March 31, 2026, fluctuations may occur with respect to (4) Changes in cash and cash equivalents with the loss of control.

(Earnings Per Share)

(1) Basic earnings per share and diluted earnings per share

(Yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Basic earnings per share	264.66	(305.81)
Continuing operations	(276.94)	(305.81)
Discontinued operations	541.60	—
Diluted earnings per share	264.66	(305.81)
Continuing operations	(276.94)	(305.81)
Discontinued operations	541.60	—

(2) Basis of calculating basic earnings per share and diluted earnings per share

(Millions of yen)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Profit attributable to common shareholders of parent	50,980	(58,970)
Continuing operations	(53,345)	(58,970)
Discontinued operations	104,325	—
Profit attributable to common shareholders of parent after adjustment for the effects of dilutive potential shares	50,980	(58,970)
Continuing operations	(53,345)	(58,970)
Discontinued operations	104,325	—

(Thousands of shares)

	For the nine months ended December 31, 2024	For the nine months ended December 31, 2025
Weighted-average number of common shares	192,626	192,832
Increase in number of common shares by share subscription rights	—	—
Weighted-average number of common shares (diluted)	192,626	192,832

Note. For the three months ended June 30, 2024, there were 163 thousand potentially dilutive common shares. However, these were excluded from the calculation of diluted earnings per share due to their anti-dilutive effect.

For the three months ended June 30, 2025, there were 89 thousand potentially dilutive common shares. However, these were excluded from the calculation of diluted earnings per share due to their anti-dilutive effect.

(Significant Subsequent Events)

Not applicable